Brukinsa Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Zanubrutinib

Indications/Uses

Adult patients w/ mantle cell lymphoma (MCL) who have received at least 1 prior therapy. Monotherapy for adult patients w/ Waldenström's macroglobulinemia (WM) who have received at least 1 prior therapy; 1st line treatment for patients unsuitable for chemo-immunotherapy. Monotherapy for adult patients w/ relapsed or refractory marginal zone lymphoma (MZL) who have received at least 1 prior anti-CD20-based regimen. Adult patients w/ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Adult patients w/ relapsed or refractory follicular lymphoma (FL) in combination w/ obinutuzumab after ≥2 lines of systemic therapy.

Dosage/Direction for Use

160 mg bd or 320 mg once daily until disease progression or unacceptable toxicity. Severe hepatic impairment 80 mg bd.

Administration

May be taken with or without food: Swallow whole w/ water. Do not open/break/chew.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EL03 - zanubrutinib ; Belongs to the class of Bruton's tyrosine kinase (BTK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Brukinsa cap 80 mg

Packing/Price

1's

Brukinsa

Manufacturer:

Catalent CTS